Structure Therapeutics’ Aleniglipron Shows “Injectable-Like Efficacy” in Promising Phase 2 Obesity Trial, Intensifying Oral GLP-1 Race
Structure Therapeutics, a rapidly emerging biotech firm, has announced compelling Phase 2 trial results for...
Knowledge and News for the Global Fight Against Cancer.
Structure Therapeutics, a rapidly emerging biotech firm, has announced compelling Phase 2 trial results for...
CytomX Therapeutics, a biopharmaceutical company focused on developing novel cancer therapies, announced on March 16,...
February marks National Cancer Prevention Month, a dedicated period for the United States to underscore...
The U.S. Food and Drug Administration (FDA) has announced a significant overhaul of its product...
Adrienne Skinner’s journey from a grim prognosis of rare, stage 4 ampullary cancer to a...
Eli Lilly has intensified its campaign against compounded versions of its blockbuster obesity drug Zepbound...
The U.S. Food and Drug Administration (FDA) has announced significant draft guidance aimed at accelerating...
The American Cancer Society’s (ACS) highly anticipated Cancer Statistics 2026 report paints a compelling picture...
The biopharmaceutical landscape is currently characterized by a complex interplay of strategic restructurings, significant workforce...
Colorectal cancer (CRC), once primarily associated with older age, is experiencing an alarming surge among...